Mohammad Arfat Ganiyani

POSTER: IBCL-1540: Sociodemographic Factors and Treatment Patterns Associated With Overall Survival in Splenic Marginal Zone Lymphoma: A Nationwide Retrospective Cohort Study (2000–2022)

Manas Pustake, Oboseh Ogedegbe, Atulya Aman Khosla, Sakditad Saowapa et autres

us (code pays fourni par la source)

IBCL-1540: Sociodemographic Factors and Treatment Patterns Associated With Overall Survival in Splenic Marginal Zone Lymphoma: A Nationwide Retrospective Cohort Study (2000–2022)

Manas Pustake, Oboseh Ogedegbe, Atulya Aman Khosla, Sakditad Saowapa et autres

us (code pays fourni par la source)

The Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study

Mohammad Arfat Ganiyani, Hiba Narvel, Arjun Pon Avudaiappan, Mrudula Thiriveedi et autres

Background: Renal cell carcinoma accounts for nearly 15,000 deaths annually in the US, and approximately 30–40% of patients present with metastatic disease (mRCC). The advent of immune checkpoint inhibitors (IO) and tyrosine kinase inhibitors (TKI) has revolutionized the treatment paradigm of patients …

us (code pays fourni par la source)

Clinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004–2022)

Manas Pustake, Atharva Railkar, Stevenson Ongsyping, Swarada Joshi et autres

Background: Prostate cancer remains one of the most prevalent malignancies and a leading cause of cancer-related mortality among men in the United States, with more than 300,000 new cases diagnosed annually. As the burden of disease continues to rise, ensuring equitable access …

us, in (code pays fourni par la source)

Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.

Parth Dhamelia, Yagnapriya Ammakola, Atulya Aman Khosla, Mohammad Arfat Ganiyani et autres

e16564 Background: Urothelial carcinoma (UC) predominantly affects older adults with a high burden of comorbidities, particularly chronic kidney disease (CKD), which affects 30–40% of patients at diagnosis and is more prevalent in advanced disease. Enfortumab vedotin plus pembrolizumab (EV+P) has become a …

us (code pays fourni par la source)

A quality improvement initiative to improve genomic testing rates in patients with prostate cancer.

Mohammad Arfat Ganiyani, Arjun Pon Avudaiappan, Mohamed Javid Raja Iyub, Dheerush Sakthivel et autres

e23316 Background: The therapeutic landscape of metastatic prostate cancer has rapidly evolved with the integration of precision oncology. Emerging data from the AMPLITUDE trial demonstrated that adding niraparib to abiraterone significantly improves rPFS in patients with BRCA-mutated mCSPC, leading to FDA approval …

us (code pays fourni par la source)

Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).

Mohammed Ganiyani, M Pustake, Oboseh John Ogedegbe, Parth Dhamelia et autres

e21605 Background: As survival after cutaneous melanoma improves, subsequent primary malignancies (SPMs) and non-cancer comorbidities increasingly influence long-term outcomes. We evaluated causes of death (COD) and clinicodemographic characteristics among decedents with melanoma and multiple primaries. Methods: We conducted a retrospective, population-based analysis …

us, in (code pays fourni par la source)

Impact of baseline severe cytopenia on post–BCMA CAR T-cell therapy outcomes in multiple myeloma: A propensity-matched multicenter study.

Jesus Alberto Gomez, Divya Samat, M Pustake, Mohammad Arfat Ganiyani et autres

e19527 Background: Severe cytopenias are common in relapsed/refractory multiple myeloma (MM) and may influence outcomes after B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy. However, comparative real-world data describing subsequent cytopenias and acute toxicities among patients with pre-index severe cytopenia …

us (code pays fourni par la source)

A systematic review and meta-analysis on safety and efficacy of Lu-177 PSMA-617 and standardized treatment in mCRPC from randomized phase II/III trials.

Rohan Garje, Mohammad Arfat Ganiyani, Ahmad Sheraz Iqbal, Dawood Hasan Syed et autres

e17069 Background: Lu-177 PSMA-617 delivers targeted β-radiation to prostate cancer cells, offering a distinct mechanism beyond androgen-signaling inhibition in metastatic castration-resistant prostate cancer (mCRPC). Pivotal trials have shown improved progression-free survival with favorable tolerability. As its clinical use expands, comparative evidence with …

us, pk, in (code pays fourni par la source)

Prognostic value of circulating tumor DNA in muscle-invasive bladder cancer treated with radical cystectomy: A systematic review and meta-analysis.

Arjun Pon Avudaiappan, Mohammad Arfat Ganiyani, Anisha Agarwal, Gabriel Valagni et autres

e16611 Background: Muscle-invasive bladder cancer (MIBC) is an aggressive disease that carries a high risk of disease recurrence. While traditional prognostic factors have been well established, circulating tumor DNA (ctDNA) has emerged as a biomarker for minimal residual disease (MRTD) in many …

us (code pays fourni par la source)

Prognostic value of PSA nadir ≤0.2 ng/mL in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.

Arjun Pon Avudaiappan, Mohammad Arfat Ganiyani, Dawood Hasan Syed, Anisha Agarwal et autres

5100 Background: The treatment landscape for metastatic castration-sensitive prostate cancer (mCSPC) has changed substantially with the adoption of early treatment intensification using androgen-receptor pathway inhibitors (ARPI) and chemotherapy, in addition to traditional androgen deprivation therapy (ADT). PSA nadir has long been used …

us, gd (code pays fourni par la source)

Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.

Atulya Aman Khosla, Parth Dhamelia, Yagnapriya Ammakola, Nitya Batra et autres

2028 Background: Patients with EGFR-mutated non–small cell lung cancer (NSCLC) frequently develop BM, and CNS progression is a common mode of failure on earlier-generation EGFR tyrosine kinase inhibitors (TKIs). After TKI failure in the setting of BM, optimal next-line systemic therapy remains …

us (code pays fourni par la source)